Hepatitis E Clinical Trials

Find Hepatitis E Clinical Trials Near You

A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Body mass index (BMI) of 18-29 kg/m2

• Must agree to use protocol-specified methods of contraception

• Negative pregnancy test

• Willing to comply with the study requirements and to provide written informed consent

Locations
Other Locations
Belgium
Atea Study Site
RECRUITING
Edegem
Contact Information
Primary
Clinical Trials Administrator
AteaClinicalTrials@ateapharma.com
888-481-1607
Time Frame
Start Date: 2026-07-13
Estimated Completion Date: 2026-12
Participants
Target number of participants: 62
Treatments
Experimental: AT-587 Dose 1 (Day 1)
AT-587 administered orally, dose 1 on Day 1
Placebo_comparator: Placebo -Dose 1 (Day 1)
Matching placebo dose 1 administered orally on Day 1
Experimental: AT-587 Dose 2 (Day 1 and Day 7)
AT-587 administrated orally, dose 2 on Day 1 and Day 7
Placebo_comparator: Placebo-Dose 2 (Day 1 and Day 7)
Matching placebo dose 2 administered orally on Day 1 and Day 7
Experimental: AT-587 Dose 3 - (Day 1)
AT-587 administered orally, dose 3 on Day 1
Placebo_comparator: Placebo - Dose 3 - (Day 1)
Matching placebo dose 3 administered orally on Day 1
Experimental: AT-587 Dose 4 - (Day 1)
AT-587 administered orally, dose 4 on Day 1
Placebo_comparator: Placebo - Dose 4- (Day 1)
Matching placebo dose 4 administered orally on Day 1
Experimental: AT-587 - Dose 5 (Day 1-7)
AT-587 - administered orally, dose 5 (QD) for 7 days
Placebo_comparator: Placebo- Dose 5 (QD) (Day 1-7)
Matching placebo dose 5 administered orally once daily (QD) for 7 days
Experimental: AT-587 - Dose 6 split (BID) (Day 1-7)
AT-587 administered orally, dose 6 daily split (BID) for 7 days
Placebo_comparator: Placebo - Dose 6 (BID) (Day 1-7)
Matching placebo administered orally dose 6 daily split (BID) for 7 days
Experimental: AT-587 - Dose 7 (QD) or split (BID) daily (Day 1-7)
AT-587 administered orally, dose 7 (QD) or split (BID) for 7 days
Placebo_comparator: Placebo - Dose 7 (QD) or split (BID) (Day 1-7)
Matching placebo administered orally, dose 7 daily (QD) or split (BID) for 7 days
Related Therapeutic Areas
Sponsors
Leads: Atea Pharmaceuticals, Inc.

This content was sourced from clinicaltrials.gov